244 related articles for article (PubMed ID: 23312272)
1. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors.
Gondi V; Hermann BP; Mehta MP; Tomé WA
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):348-54. PubMed ID: 23312272
[TBL] [Abstract][Full Text] [Related]
2. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors.
Gondi V; Hermann BP; Mehta MP; Tomé WA
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e487-93. PubMed ID: 22209148
[TBL] [Abstract][Full Text] [Related]
3. Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy: a prospective study.
Tsai PF; Yang CC; Chuang CC; Huang TY; Wu YM; Pai PC; Tseng CK; Wu TH; Shen YL; Lin SY
Radiat Oncol; 2015 Dec; 10():253. PubMed ID: 26654128
[TBL] [Abstract][Full Text] [Related]
4. Hippocampus-sparing radiotherapy using volumetric modulated arc therapy (VMAT) to the primary brain tumor: the result of dosimetric study and neurocognitive function assessment.
Kim KS; Wee CW; Seok JY; Hong JW; Chung JB; Eom KY; Kim JS; Kim CY; Park YH; Kim YJ; Kim IA
Radiat Oncol; 2018 Feb; 13(1):29. PubMed ID: 29463267
[TBL] [Abstract][Full Text] [Related]
5. A Radiation-Induced Hippocampal Vascular Injury Surrogate Marker Predicts Late Neurocognitive Dysfunction.
Farjam R; Pramanik P; Aryal MP; Srinivasan A; Chapman CH; Tsien CI; Lawrence TS; Cao Y
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):908-15. PubMed ID: 26530761
[TBL] [Abstract][Full Text] [Related]
6. Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance.
Martinage G; Hong AM; Fay M; Thachil T; Roos D; Williams N; Lo S; Fogarty G
Radiat Oncol; 2018 Jul; 13(1):132. PubMed ID: 30029684
[TBL] [Abstract][Full Text] [Related]
7. Hippocampal radiotherapy dose constraints for predicting long-term neurocognitive outcomes: mature data from a prospective trial in young patients with brain tumors.
Goda JS; Dutta D; Krishna U; Goswami S; Kothavade V; Kannan S; Maitre M; Bano N; Gupta T; Jalali R
Neuro Oncol; 2020 Nov; 22(11):1677-1685. PubMed ID: 32227185
[TBL] [Abstract][Full Text] [Related]
8. Association between hippocampal dose and memory in survivors of childhood or adolescent low-grade glioma: a 10-year neurocognitive longitudinal study.
Acharya S; Wu S; Ashford JM; Tinkle CL; Lucas JT; Qaddoumi I; Gajjar A; Krasin MJ; Conklin HM; Merchant TE
Neuro Oncol; 2019 Sep; 21(9):1175-1183. PubMed ID: 30977510
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Imaging Biomarkers of Damage to Critical Memory Regions Are Associated With Post-Radiation Therapy Memory Performance in Brain Tumor Patients.
Tringale KR; Nguyen TT; Karunamuni R; Seibert T; Huynh-Le MP; Connor M; Moiseenko V; Gorman MK; Marshall A; Tibbs MD; Farid N; Simpson D; Sanghvi P; McDonald CR; Hattangadi-Gluth JA
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):773-783. PubMed ID: 31408667
[TBL] [Abstract][Full Text] [Related]
10. A prospective evaluation of hippocampal radiation dose volume effects and memory deficits following cranial irradiation.
Ma TM; Grimm J; McIntyre R; Anderson-Keightly H; Kleinberg LR; Hales RK; Moore J; Vannorsdall T; Redmond KJ
Radiother Oncol; 2017 Nov; 125(2):234-240. PubMed ID: 29128167
[TBL] [Abstract][Full Text] [Related]
11. Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG).
Grosu AL; Frings L; Bentsalo I; Oehlke O; Brenner F; Bilger A; Fennell JT; Rothe T; Schneider-Fuchs S; Graf E; Schmoor C; Beck J; Becker G; Bock M; Egger K; Urbach H; Lahmann C; Popp I
BMC Cancer; 2020 Jun; 20(1):532. PubMed ID: 32513138
[TBL] [Abstract][Full Text] [Related]
12. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.
Gondi V; Pugh SL; Tome WA; Caine C; Corn B; Kanner A; Rowley H; Kundapur V; DeNittis A; Greenspoon JN; Konski AA; Bauman GS; Shah S; Shi W; Wendland M; Kachnic L; Mehta MP
J Clin Oncol; 2014 Dec; 32(34):3810-6. PubMed ID: 25349290
[TBL] [Abstract][Full Text] [Related]
13. Hippocampal-sparing and target volume coverage in treating 3 to 10 brain metastases: A comparison of Gamma Knife, single-isocenter VMAT, CyberKnife, and TomoTherapy stereotactic radiosurgery.
Zhang I; Antone J; Li J; Saha S; Riegel AC; Vijeh L; Lauritano J; Marrero M; Salas S; Schulder M; Zinkin H; Goenka A; Knisely J
Pract Radiat Oncol; 2017; 7(3):183-189. PubMed ID: 28477798
[TBL] [Abstract][Full Text] [Related]
14. Hippocampal-sparing radiotherapy: the new standard of care for World Health Organization grade II and III gliomas?
Pinkham MB; Bertrand KC; Olson S; Zarate D; Oram J; Pullar A; Foote MC
J Clin Neurosci; 2014 Jan; 21(1):86-90. PubMed ID: 24090519
[TBL] [Abstract][Full Text] [Related]
15. Hippocampal-sparing radiotherapy and neurocognitive impairment: A systematic literature review.
Giuseppe ZR; Silvia C; Eleonora F; Gabriella M; Marica F; Silvia C; Mario B; Francesco D; Savino C; Milly B; Frezza GP; Maurizio Z; Morganti AG
J Cancer Res Ther; 2020; 16(6):1215-1222. PubMed ID: 33342776
[TBL] [Abstract][Full Text] [Related]
16. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas.
Cho KH; Hall WA; Gerbi BJ; Higgins PD; McGuire WA; Clark HB
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1133-41. PubMed ID: 10613305
[TBL] [Abstract][Full Text] [Related]
17. Left hippocampal dosimetry correlates with visual and verbal memory outcomes in survivors of pediatric brain tumors.
Zureick AH; Evans CL; Niemierko A; Grieco JA; Nichols AJ; Fullerton BC; Hess CB; Goebel CP; Gallotto SL; Weyman EA; Gaudet DE; Nartowicz JA; Ebb DH; Jones RM; MacDonald SM; Tarbell NJ; Yock TI; Pulsifer MB
Cancer; 2018 May; 124(10):2238-2245. PubMed ID: 29499085
[TBL] [Abstract][Full Text] [Related]
18. Hippocampal dose from stereotactic radiosurgery for 4 to 10 brain metastases: Risk factors, feasibility of dose reduction via re-optimization, and patient outcomes.
Birer SR; Olson AC; Adamson J; Hood R; Susen M; Kim G; Salama JK; Kirkpatrick JP
Med Dosim; 2017 Winter; 42(4):310-316. PubMed ID: 28760560
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the impact of hippocampal sparing during whole brain radiotherapy on neurocognitive functions: A preliminary report of a prospective phase II study.
Lin SY; Yang CC; Wu YM; Tseng CK; Wei KC; Chu YC; Hsieh HY; Wu TH; Pai PC; Hsu PW; Chuang CC
Biomed J; 2015; 38(5):439-49. PubMed ID: 25994802
[TBL] [Abstract][Full Text] [Related]
20. Increased cochlear radiation dose predicts delayed hearing loss following both stereotactic radiosurgery and fractionated stereotactic radiotherapy for vestibular schwannoma.
Patel KS; Ng E; Kaur T; Miao T; Kaprealian T; Lee P; Pouratian N; Selch MT; De Salles AAF; Gopen Q; Tenn S; Yang I
J Neurooncol; 2019 Nov; 145(2):329-337. PubMed ID: 31552587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
